SEC Form 4 · accession 0001179110-19-000343
CATABASIS PHARMACEUTICALS INC · CATB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Anthony Gregg Lapointe
Director
Period of report
Jan 3, 2019
Accepted (ET)
Jan 4, 2019 · 9:24 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001454789
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $4.90 | Jan 3, 2019 | A | 2,800 | A | — | Jan 2, 2029 | Common Stock | 2,800 | 2,800 | D |
Explanation of responses
- F1This option was granted on January 3, 2019. The option is scheduled to vest as to one-third of the shares of common stock underlying the option on each anniversay of the grant date until the third anniversay of the grant date.